Market Signal Briefing

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in KHNGF, KHNGY over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The content of this article is for informational purposes only. It constitutes neither a solicitation or an offer or recommendation to buy or sell any investment instruments or to engage in any other transactions. The information provided in this article is provided “as is” and “as available” without warranty of any kind. Your use of this information is entirely at your own risk. Although the information in this article is obtained or compiled from sources we believe to be reliable, we cannot and do not guarantee or make any representation or warranty, either expressed or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data made available in this article. In no event shall Oyat be liable for any decision made or action or inaction taken in reliance on any information or data in this article or on any linked documents. All trading in financial instruments entails risk. Investors should evaluate their intended investments in light of their knowledge and experience, financial positions and investment objectives—or speak to a financial advisor—before making any investment decisions. Past performance is not indicative of future results.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

In a reorganization, the beauty giant leans into higher-end beauty brands and mass-market fragrances.

September 30, 2025 1:46 AM EDT | Source: Tincorp Metals Inc.
Vancouver, British Columbia--(Newsfile Corp. - September 30, 2025) - Tincorp Metals Inc. (TSXV: TIN) (OTCQB: TINFF) ("Tincorp" or the "Company") is pleased to announce that it has completed the previously announced sale (the "Transaction") of Tincorp's wholly owned subsidiary, Whitehorse Gold (Yukon) Corp. ("Whitehorse Gold") to Blue Jay Gold Corp. ("Blue Jay"), a private reporting issuer recently spun out of Riverside Resources Inc. The Transaction closed on September 29, 2025. Whitehorse Gold holds a 100% interest in the Skukum Gold Project (the "Project") located in Yukon, Canada.

Under the terms of the share purchase agreement between the parties (the "Agreement"), the total consideration payable by Blue Jay for the acquisition of the shares of Whitehorse Gold was structured as two payments: (i) at closing, Blue Jay issued 500,000 common shares of Blue Jay and 250,000 common share purchase warrants (each, a "Warrant"), having an aggregate value of $300,000; and (ii) $275,000, payable in cash and/or shares at Blue Jay's election, is to be paid to Tincorp on the first anniversary of the closing date. Each Warrant entitles the Company to acquire one additional common share at an exercise price of $0.90 per share for a period of two years from the date of issuance, subject to certain acceleration provisions. A $25,000 cash deposit previously advanced by Blue Jay upon execution of the letter of intent has been credited towards the total purchase price. Blue Jay has also assumed the security demand obligations related to the Project (the "Security Demand").

In addition, Blue Jay has agreed to pay an incentive payment comprised of $5 per ounce of gold equivalent ("AuEq") in excess of a cumulative total of 2 million ounces AuEq identified on the Project within 5 years of the closing date of the Transaction, as determined based on an updated technical report to be prepared in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects by Blue Jay. The incentive amount payable by Blue Jay will be paid in cash and/or shares at Blue Jay's discretion within 90 days of the 5 -year anniversary of the closing date and is subject to adjustment based on remediation expenditures incurred by Blue Jay in excess of the amount of the Security Demand.

"The closing of this deal marks a significant step in Tincorp's continued shift toward pursuing new growth opportunities," said Victor Feng, Interim CEO of Tincorp. "We are pleased that the Skukum Gold Project is in the hands of a company committed to advancing exploration in the Yukon responsibly. This transaction also gives Tincorp the ability to participate in any future success at Skukum through our prospective equity position in Blue Jay, which is expanding its portfolio of gold projects in Ontario and now the Yukon."

About Tincorp

Tincorp Metals Inc. is a mineral exploration company focused on tin projects in Bolivia. The Company owns 100% of its Porvenir Project and has signed an agreement to acquire a 100% interest in the nearby SF Project, both located 70 km southeast of Oruro, Bolivia.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (collective, "forward looking statements") within the meaning of applicable Canadian and U.S. securities legislation. All statements, other than statements of historical fact included in this release, including, without limitation, statements regarding the completion of the Transaction the expected benefits of the Transaction to Tincorp; future exploration and acquisition activities; the potential future payment of an incentive amount by Blue Jay; the advancement of Tincorp's Bolivian assets and pursuit of new growth opportunities; and Tincorp's potential future participation in the Project through an equity interest in Blue Jay are forward-looking statements. Estimates of Mineral Reserves and Mineral Resources are also forward-looking information because they incorporate estimates of future developments including future mineral prices, costs and expenses and the amount of minerals that will be encountered if a property is developed.

Forward-looking statements are often, but not always, identified by words or phrases such as "expects", "is expected", "anticipates", "believes", "plans", "projects", "estimates", "assumes", "intends", "strategies", "targets", "goals", "forecasts", "objectives", "budgets", "schedules", "potential" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions. Forward-looking statements are based on the opinions, assumptions, factors and estimates of management considered reasonable at the date the statements are made. The opinions, assumptions, factors and estimates which may prove to be incorrect, include, but are not limited to: that the Company will be able to obtain and maintain governmental approvals, permits and licenses in connection with its current and planned operations, development and exploration activities, including at the Project.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Forward-looking information is provided herein for the purpose of giving information about the Transaction referred and its expected impact. Readers are cautioned that such information may not be appropriate for other purposes. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ from those described in forward-looking statements, there may be other factors that cause such actions, events or results to differ materially from those anticipated. There can be no assurance that forward-looking statements will prove to be accurate and accordingly readers are cautioned not to place undue reliance on forward-looking statements.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Additional information in relation to the Company, including the Company's most recent management discussion & analysis, can be obtained under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Company's website at www.tincorp.com.

CAUTIONARY NOTE TO US INVESTORS

The technical and scientific information contained herein has been prepared in accordance with NI 43-101, which differs from the standards adopted by the U.S. Securities and Exchange Commission (the "SEC"). Accordingly, the technical and scientific information contained herein, including any estimates of mineral reserves and mineral resources, may not be comparable to similar information disclosed by U.S. companies subject to the disclosure requirements of the SEC.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268488

, /PRNewswire/ --

Tetragon has released its Monthly Factsheet for August 2025.

Net Asset Value: $3,626m
Fully Diluted NAV per Share: $39.41
Share Price (TFG NA): $18.35
Monthly NAV per Share Total Return: 2.6%
Monthly Return on Equity: 3.2%
Most Recent Quarterly Dividend: $0.11
Dividend Yield: 2.4%

Please refer to important disclosures on page three of the Monthly Factsheet.

Please click below to access the Monthly Factsheet.

August 2025 Factsheet

About Tetragon:

Tetragon is a Guernsey closed-ended investment company. Its non-voting shares are listed on Euronext in Amsterdam, a regulated market of Euronext Amsterdam N.V., and also traded on the Specialist Fund Segment of the Main Market of the London Stock Exchange. Our investment manager is Tetragon Financial Management LP. Find out more at www.tetragoninv.com.

Tetragon's non-voting shares are subject to restrictions on ownership by U.S. persons and are not intended for European retail investors.

Please see: https://www.tetragoninv.com/shareholders/additional-information.

Tetragon Investor Relations:
Yuko Thomas
[email protected]

Press Inquiries:
Prosek Partners
[email protected]
U.K. +44 20 3890 9193
U.S. +1 212 279 3115

This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in the United States or to conduct a public offer of securities in the United States. In addition, Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940, and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets under Section 1:107 of the Financial Markets Supervision Act as a collective investment scheme from a designated country.    

SOURCE Tetragon Financial Group Limited

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

NEW YORK--(BUSINESS WIRE)--Regulatory News:

Coty Inc. (NYSE: COTY) (Paris: COTY) (“Coty” or “the Company”) today announced it will more closely integrate its Prestige Beauty and Mass Fragrance businesses, thereby refocusing the Company on its heritage and core strengths, to drive sustainable profitable growth and accelerate value creation. In addition, Coty has launched a comprehensive strategic review of its Consumer Beauty business to unleash its full potential.

Coty is a global leader in prestige and mass fragrance. To maximize growth prospects and synergies, Coty will initiate organizational changes to drive much closer integration and coordination between Prestige & Consumer Beauty fragrances, which account for 69% of Coty’s sales. Under this new structure, Coty will fully leverage its scale across R&D, consumer insights, manufacturing, and distribution to strengthen the Company’s revenue and profit engine.

“This next phase of our transformation is about clarity and focus,” said Sue Nabi, CEO of Coty. “By more closely integrating all our fragrance and scenting brands, we unlock the full power of our scale. The fragrance category continues to outperform the global beauty market and already drives the majority of our revenues and profits. Coty has a proven right to win at all price points of scenting, from $5 to $500, and is already making strong headway in the exciting new $7 billion mist market.”

Coty’s Prestige division will continue to steadily grow its cosmetics and skincare businesses. With an extensive IP portfolio and advanced formulations, Coty will increase its presence in these categories with strong margin potential and significant runway for global growth. Coty remains fully committed to growing its prestige portfolio through blockbuster launches and brand elevation.

Sue Nabi added: “This new structure will also drive renewed momentum and sharper focus for Consumer Beauty, positioning it to compete more effectively in the evolving beauty landscape. We have asked Gordon von Bretten, Coty Board member and former Chief Transformation Officer, to lead Consumer Beauty as President, reporting to me. Mr. von Bretten will have end-to-end responsibility for delivering the full potential of our strong brands in the mass cosmetics, mass skin, and personal care businesses. He will also lead the strategic review and join Coty’s Executive Committee.”

The strategic review will focus on Coty’s $1.2 billion revenue mass color cosmetics business, including brands such as CoverGirl, Rimmel, Sally Hansen, and Max Factor, and its distinct Brazil business comprised of local Brazilian brands that generate close to $400 million revenue. The review will assess a full range of alternatives including partnerships, divestitures, spin-offs, and other potential strategic actions, with the objective of maximizing long-term value and strengthening the balance sheet. The Company will provide updates when appropriate, including when specific actions are approved by the Board.

“We are taking decisive steps on Consumer Beauty and I am honored to lead this next phase of value creation together with Ms. Nabi,” said Mr. von Bretten. “Our agenda is clear: realize the full potential of our market-leading brands by focusing the portfolio, elevating product excellence, and driving productivity with discipline so that performance is visible in growth, margin expansion, and cash generation.”

As part of this organizational redesign, Stefano Curti, Chief Brands Officer of Consumer Beauty, and Alexis Vaganay, Chief Commercial Officer of Consumer Beauty, will step down from their roles.

Ms. Nabi added, “I wish to thank Stefano and Alexis for their contributions and commitment to our Consumer Beauty transformation over the last 5 years.”

Coty has retained Citi to advise on the comprehensive strategic review.

About Coty Inc.

Founded in Paris in 1904, Coty is one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. Coty serves consumers around the world, selling prestige and mass market products in over 120 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and we are committed to protecting the planet. Learn more at coty.com or on LinkedIn and Instagram.

Forward Looking Statements

Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Coty’s current views with respect to, among other things, the strategic review of Coty’s consumer beauty business, including its mass color cosmetics business and associated brands and its distinct Brazil business comprised of local Brazilian brands, and any transactions related thereto, use of proceeds from any transaction and the timing and outcome of the strategic review. These forward-looking statements are generally identified by words or phrases, such as “anticipate”, “are going to”, “estimate”, “plan”, “project”, “expect”, “believe”, “intend”, “foresee”, “forecast”, “will”, “may”, “should”, “outlook”, “continue”, “temporary”, “target”, “aim”, “potential”, “goal” , “realize” and similar words or phrases. These statements are based on certain assumptions and estimates that Coty considers reasonable and are not guarantees of Coty’s future performance, but subject to a number of risks and uncertainties, many of which are beyond Coty’s control, which could cause actual events or results to differ materially from such statements, including risks and uncertainties relating to the results of the strategic review of Coty’s consumer beauty business, associated brands and Brazilian operations and whether such strategic review will result in any transactions and the amount of proceeds from any such transactions.

Please see below information about transactions made under the third tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Date on which the buy-back tranche was announced: 23 July 2025.

The duration of the buy-back tranche: 24 July to no later than 27 October 2025.

Further information on the tranche can be found in the stock market announcement on its commencement dated 23 July 2025, available here: https://newsweb.oslobors.no/message/651645

From 22 September to 26 September 2025, Equinor ASA has purchased a total of 1,343,874 own shares at an average price of NOK 250.4636 per share.

Overview of transactions:

DateTrading venueAggregated daily volume (number of shares)Daily weighted average share price (NOK)Total daily transaction value (NOK)     22 SeptemberOSE271,914241.902465,776,649.19 CEUX    TQEX        23 SeptemberOSE259,402245.681663,730,298.40 CEUX    TQEX        24 SeptemberOSE272,311251.608968,515,871.17 CEUX    TQEX        25 SeptemberOSE282,867256.405972,528,767.72 CEUX    TQEX        26 SeptemberOSE257,380256.585166,039,873.04 CEUX    TQEX        Total for the periodOSE1,343,874250.4636336,591,459.52 CEUX    TQEX        Previously disclosed buy-backs under the trancheOSE10,706,608250.49582,681,960,251.17CEUX   TQEX   Total10,706,608250.49582,681,960,251.17     Total buy-backs under the tranche (accumulated)OSE12,050,482250.49223,018,551,710.69CEUX   TQEX   Total12,050,482250.49223,018,551,710.69 Following the completion of the above transactions, Equinor ASA owns a total of 38,336,337 own shares, corresponding to 1.50% of Equinor ASA’s share capital, including shares under Equinor’s share savings programme (excluding shares under Equinor’s share savings programme, Equinor owns a total of 28,427,670 own shares, corresponding to 1.11% of the share capital).

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: A overview of all transactions made under the buy-back tranche that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Contact details:

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584

Detailed overview of transactions

LONDON, UNITED KINGDOM / ACCESS Newswire / September 30, 2025 / Genflow (LSE:GENF)(OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025. Chairman's Statement It is my pleasure to update shareholders of Genflow Biosciences Plc ("Genflow" or the "Company") on our performance during the first six months of 2025.

Interim Results for the period ended 30 June 2025 LONDON, UK / ACCESS Newswire / September 30, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose Shares are admitted to the equity shares (transition) category of the Official List, announces its unaudited interim results for the six-month period ended 30 June 2025. All financial amounts are stated in GBP British pounds unless otherwise indicated.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in STT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Report to be released at approximately 7:00 AM CEST on October 14, 2025
One live video webcast for analysts, investors and journalists at 9:00 AM CEST

, /PRNewswire/ -- Ericsson's (NASDAQ: ERIC) financial report for the third quarter 2025 will be published at approximately 7:00 AM CEST on October 14, 2025. The company will issue a press release with the complete financial report attached, including tables, in PDF format. Following publication of the press release, the financial report will be available on Ericsson's website: https://www.ericsson.com/en/investors

President and CEO Börje Ekholm and CFO Lars Sandström will comment on the report and take questions at a live video webcast at 9:00 AM CEST (8:00 AM BST London, 3:00 AM EDT New York).

Join the webcast or please go to www.ericsson.com/investors

To ask a question: Access dial-in information here

The webcast will be available on-demand after the event and can be viewed on our website.

NOTES TO EDITORS:

FOLLOW US:

Subscribe to Ericsson press releases
Subscribe to Ericsson blog posts
https://x.com/ericsson
https://www.facebook.com/ericsson
https://www.linkedin.com/company/ericsson

MORE INFORMATION AT:
Ericsson Newsroom
[email protected]  (+46 10 719 69 92)
[email protected]  (+46 10 719 00 00)

ABOUT ERICSSON:
Ericsson's high-performing networks provide connectivity for billions of people every day. For nearly 150 years, we've been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality. www.ericsson.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/ericsson/r/invitation-to-media-and-analyst-briefing-for-ericsson-q3-2025-report,c4241509

The following files are available for download:

SOURCE Ericsson

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Accuray Incorporated (NASDAQ:ARAY) Shareholder/Analyst Call September 29, 2025 4:30 PM EDT

Company Participants

Suzanne Winter - President, CEO & Director
Mu Lee - Senior Vice President of Research & Product Development
Seth Blacksburg - Senior VP & Chief Medical Officer

Conference Call Participants

Shalom Kalnicki
Jonathan Haas
Giuseppe Sasso
John Kresl

Presentation

Suzanne Winter
President, CEO & Director

Good afternoon, everyone, and welcome to Accuray's Analyst briefing. We're coming to you from the ASTRO conference in San Francisco for 2025. We'll be leading a discussion about leading in the adaptive era of radiation medicine. I want to welcome everyone. It's absolutely a privilege to be here with a distinguished group of our global key opinion leaders in radiation oncology as well as our research analysts and shareholders who are joining us virtually. Our analysts that cover medtech and radiation oncology market, and they write notes for investors and advise on investment decisions. You're all experts and who -- how we shape, how we understand innovation in medical technology and how we bridge clinical insight, patient outcomes and investment perspectives.

As you know, at Accuray, we believe our role is not just to build devices, but to advance medicine by partnering with clinicians and researchers who set the standard of care. Today, we're going to have an open dialogue about the trends in adaptive radiation medicine treatment. We'll be sharing science behind the technology and hearing perspectives from our esteemed panel, and we'll be exploring how we can make the greatest impact for patients and health care systems to deliver clinical and economic value. So thank you for taking the time to be here. We'll dive into the conversation. I'll make a few opening remarks, and then we'll go right into the discussion.

Let's start with our safe harbor statement. And again, this is a presentation that

Recommended For You

DULUTH, Ga.--(BUSINESS WIRE)--The latest Primerica Household Budget Index™ (HBI™) data, a monthly economic metric that examines how inflation and wage trends impact the ability of middle-income families to afford life's everyday necessities, was 100.2% in August, a 0.1% increase from a month ago and up 0.8% from a year ago. The Consumer Price Index (CPI), which measures inflation for a comprehensive basket of goods for all U.S. households, rose 2.9% in August compared to a year ago marking the.

Exxon Mobil logo and stock graph are seen through a magnifier displayed in this illustration taken September 4, 2022. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

CompaniesSept 30 (Reuters) - ExxonMobil's

(XOM.N), opens new tab chief executive Darren Woods sought assurances from Mozambique's president Daniel Chapo last week about security for a proposed $30 billion gas terminal in the country ahead of a decision to greenlight the project, the Financial Times reported on Tuesday.

Woods raised concerns about the dangers posed by a jihadist insurgency in Mozambique’s north-eastern Cabo Delgado region, where Exxon is planning to build Africa's largest LNG facility, the report said, citing sources with knowledge of the talks.

Sign up here.

Reuters could not immediately verify the report. Exxon did not immediately respond to a Reuters' request for comment. The Mozambican presidency could not be reached immediately.

Islamic State-linked militants launched an insurgency in the northern gas-rich province of Cabo Delgado in 2017, killing thousands of civilians, destroying livelihoods and internally displacing hundreds of thousands, aid agencies say. The insurgency has disrupted multi-billion-dollar energy projects.

Woods and Chapo also discussed plans by TotalEnergies

(TTEF.PA), opens new tab to resume work on a nearby LNG facility being developed by the French oil major and lift a force majeure, the FT said.

TotalEnergies had halted work on the project and declared force majeure in 2021 after insurgents attacked the northern town of Palma, a logistics hub near the site.

"We strongly believe that the ExxonMobil project, if implemented, will make a huge difference in the economy of Mozambique and, as a consequence, in the life of Mozambicans," Chapo told the FT in an emailed statement.

An Exxon spokesperson told the FT that the company is working closely with Total, the Mozambique government and its partners in the LNG project to ensure the right conditions are met to enable a final investment decision on the development.

Reporting by Rhea Rose Abraham in Bengaluru; Editing by Mrigank Dhaniwala

Our Standards: The Thomson Reuters Trust Principles., opens new tab

"The competitive reality is that the Chinese are the 700-pound gorilla in the EV industry," Ford CEO Jim Farley said of Chinese automakers.

Kym Illman via Getty Images

2025-09-30T04:24:42Z

Ford CEO Jim Farley says China is dominating the global EV market.
"The competitive reality is that the Chinese are the 700-pound gorilla in the EV industry," he said.
Farley said China's success stems from the government's support, which their automakers get to enjoy.

Ford CEO Jim Farley says there's barely any contest between Chinese and American automakers when it comes to dominating in EVs.

"The competitive reality is that the Chinese are the 700-pound gorilla in the EV industry," Farley told The Verge's "Decoder" podcast in an episode that aired Monday.

"There's no real competition from Tesla, GM, or Ford with what we've seen from China. It is completely dominating the EV landscape globally and more and more outside of China," he added.

Representatives for Farley at Ford did not respond to a request for comment from Business Insider.

Farley told guest host and journalist Joanna Stern that China's dominance in the industry stemmed from the generous government support its automakers enjoyed.

"China's successful for good reason. It has great innovation at a very low cost," Farley said.

"There's hundreds of companies, and they're all sponsored by their local governments, so they have huge subsidies. It's new brands. It's BYD and Geely, and companies like Nio and Xiaomi, many of which have never been in the car business before, and that's a big advantage for them," he added.

Farley has talked about China's lead in the EV race on multiple occasions.

In June, Farley said during a panel at the Aspen Ideas Festival that China's EV progress is the "most humbling thing" he has ever seen.

"They have far superior in-vehicle technology. Huawei and Xiaomi are in every car," Farley said. "You get in, you don't have to pair your phone. Automatically, your whole digital life is mirrored in the car."

"We are in a global competition with China, and it's not just EVs. And if we lose this, we do not have a future Ford," he added.

Farley praised Chinese tech giant Xiaomi's maiden electric vehicle, the SU7, in an episode of "The Fully Charged Podcast," which aired in October 2024.

"I don't like talking about the competition so much, but I drive the Xiaomi," Farley said.

"We flew one from Shanghai to Chicago, and I've been driving it for six months now, and I don't want to give it up," he added.

Farley isn't the only one who sees China's dominance in EVs as a byproduct of the country's lower labor costs and generous subsidies.

The Centre for Strategic & International Studies said in a report published last year that China's government has spent at least $230 billion funding local EV makers between 2009 and 2023.

"There's not something magical when you take it apart that's allowing these really impressive cost structures," RJ Scaringe, the CEO of American EV maker Rivian, told the "Everything Electric" podcast in an episode that aired in September.

"There's no secret magic thing that you're like, 'Oh, aha, they did this.' But rather it's the compounding benefits of a lower cost of capital," he added.

Ford

China

Read next

TOKYO--(BUSINESS WIRE)--Accenture (NYSE: ACN) is set to acquire Aidemy Inc. (President: Akihiko Ishikawa, Tokyo Stock Exchange Growth Market, Securities Code: 5577), after completing a tender offer. Integrating Aidemy into Accenture will further strengthen LearnVantage, Accenture’s learning and reskilling service, which is helping clients around the world to identify and fill skill gaps in their businesses, and train their people in areas like generative AI which are essential for promoting enterprise reinvention utilizing advanced technologies. Additionally, this acquisition will strengthen Accenture’s ability to provide end-to-end support for clients to reinvent with AI—from talent development to ensuring the sustained use of AI systems—by leveraging Aidemy’s expertise in developing, implementing, and operating AI systems optimized for a wide range of tasks and industries.

During the tender offer period from August 15, 2025 (Friday) through September 29, 2025 (Monday), the number of Aidemy’s common shares and stock acquisition rights tendered to Accenture exceeded the minimum number of shares to be purchased, and accordingly, the tender offer was successfully completed. Upon completion of the settlement of the tender offer, Aidemy will become a subsidiary of Accenture. Accenture is to purchase all remaining shares and stock acquisition rights in the coming months, after which Aidemy will be delisted from the Tokyo Stock Exchange.

Aidemy provides AI and digital transformation (DX) support services for enterprises, including talent development, organizational transformation consulting and AI system development. For individuals, Aidemy has developed high expertise in areas such as reskilling programs focused on AI, DX and data analysis, as well as career support. Founded in June 2014, Aidemy was listed on the Tokyo Stock Exchange Growth Market in June 2023. Going forward, approximately 130 professionals engaged within Aidemy and its group of companies (fact-real, MABOROSHI, to-R) responsible for system development and operations will join Accenture to support clients in advancing their talent strategies and organizational transformation.

Atsushi Egawa, CEO, Accenture, Japan, and co-CEO, Asia-Pacific, said: "There is a growing demand among companies to rapidly drive comprehensive total enterprise reinvention utilizing cutting edge technologies, including generative AI. To ensure the success of such transformations, it is essential not only to redefine ways of working and skills based on digital and AI utilization, but also to focus on talent development and redeployment. By combining the strengths of Aidemy group and Accenture, we can support enhancing competitiveness and sustainable growth by maximizing the potential of our clients’ workforces. Additionally, we aim to fundamentally transform the way learning is conducted and contribute to building a foundation that supports the growth of society as a whole."

Akihiko Ishikawa, President, Aidemy said: "Aidemy group has over its history provided end-to-end support across the AI and DX domains in fields ranging from education to development and implementation, thereby helping to drive corporate transformation. We are confident that joining Accenture will enable us to further expand our expertise in talent development and our technical capabilities for AI system development. In particular, we will strengthen reskilling which can be utilized in on-the-job activities and provide support for organizational adoption, which in turn will accelerate companies’ processes for incorporating AI, generative AI, and other advanced technologies into their businesses. Under our mission, 'Bringing advanced technology into the economy,' we will accelerate efforts to strengthen the competitiveness and talent development of leading companies in Japan and around the world, and contribute to the digitalization of society."

According to a survey by the World Economic Forum, on average, workers can expect that two-fifths (39%) of their existing skill sets will be transformed or become outdated over the 2025-2030 period1. This makes continuous investment in talent development essential for companies to maintain their competitiveness. In this context, Accenture announced in March 2024 a US$1 billion investment over three years to establish LearnVantage, a comprehensive service which supports talent strategies, reskilling and upskilling for clients around the globe. To strengthen this offering, Accenture has made a series of acquisitions including Udacity, Award Solutions, TalentSprint and Ascendient Learning.

About Accenture

Accenture is a leading global professional services company that helps the world’s leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 779,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world’s leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. Our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at accenture.com

Forward-Looking Statements

Except for the historical information and discussions contained herein, statements in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “should,” “likely,” “anticipates,” “aspires,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” “positioned,” “outlook,” “goal,” “target” and similar expressions are used to identify these forward-looking statements. These statements are not guarantees of future performance nor promises that goals or targets will be met, and involve a number of risks, uncertainties and other factors that are difficult to predict and could cause actual results to differ materially from those expressed or implied. These risks include, without limitation, risks that: Accenture and Aidemy will not be able to close the transaction in the time period anticipated, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions; the transaction might not achieve the anticipated benefits for Accenture; Accenture’s results of operations have been, and may in the future be, adversely affected by volatile, negative or uncertain economic and geopolitical conditions and the effects of these conditions on the company’s clients’ businesses and levels of business activity; Accenture’s business depends on generating and maintaining client demand for the company’s services and solutions including through the adaptation and expansion of its services and solutions in response to ongoing changes in technology and offerings, and a significant reduction in such demand or an inability to respond to the evolving technological environment could materially affect the company’s results of operations; risks and uncertainties related to the development and use of AI could harm the company’s business, damage its reputation or give rise to legal or regulatory action; if Accenture is unable to match people and their skills with client demand around the world and attract and retain professionals with strong leadership skills, the company’s business, the utilization rate of the company’s professionals and the company’s results of operations may be materially adversely affected; Accenture faces legal, reputational and financial risks from any failure to protect client and/or company data from security incidents or cyberattacks; the markets in which Accenture operates are highly competitive, and Accenture might not be able to compete effectively; Accenture’s ability to attract and retain business and employees may depend on its reputation in the marketplace; if Accenture does not successfully manage and develop its relationships with key ecosystem partners or fails to anticipate and establish new alliances in new technologies, the company’s results of operations could be adversely affected; Accenture’s profitability could materially suffer due to pricing pressure, if the company is unable to remain competitive, if its cost-management strategies are unsuccessful or if it experiences delivery inefficiencies or fail to satisfy certain agreed-upon targets or specific service levels; changes in Accenture’s level of taxes, as well as audits, investigations and tax proceedings, or changes in tax laws or in their interpretation or enforcement, could have a material adverse effect on the company’s effective tax rate, results of operations, cash flows and financial condition; Accenture’s results of operations could be materially adversely affected by fluctuations in foreign currency exchange rates; Accenture’s debt obligations could adversely affect its business and financial condition; changes to accounting standards or in the estimates and assumptions Accenture makes in connection with the preparation of its consolidated financial statements could adversely affect its financial results; as a result of Accenture’s geographically diverse operations and strategy to continue to grow in key markets around the world, the company is more susceptible to certain risks; if Accenture is unable to manage the organizational challenges associated with its size, the company might be unable to achieve its business objectives; Accenture might not be successful at acquiring, investing in or integrating businesses, entering into joint ventures or divesting businesses; Accenture’s business could be materially adversely affected if the company incurs legal liability; Accenture’s work with government clients exposes the company to additional risks inherent in the government contracting environment; Accenture’s global operations expose the company to numerous and sometimes conflicting legal and regulatory requirements; if Accenture is unable to protect or enforce its intellectual property rights or if Accenture’s services or solutions infringe upon the intellectual property rights of others or the company loses its ability to utilize the intellectual property of others, its business could be adversely affected; Accenture may be subject to criticism and negative publicity related to its incorporation in Ireland; as well as the risks, uncertainties and other factors discussed under the “Risk Factors” heading in Accenture plc’s most recent Annual Report on Form 10-K, as updated in Item 1A, “Risk Factors” in its Quarterly Report on Form 10-Q for the second quarter of fiscal 2025, and other documents filed with or furnished to the Securities and Exchange Commission. In addition, the timing and amount of costs related to our business optimization actions and the nature and extent of benefits realized from such actions are subject to uncertainties and other factors, including local country consultation processes and regulations, and may differ from our current expectations and estimates. Statements in this news release speak only as of the date they were made, and Accenture undertakes no duty to update any forward-looking statements made in this news release or to conform such statements to actual results or changes in Accenture’s expectations.

1Source: Future of Jobs Report 2025, World Economic Forum, January 7, 2025.

Copyright © 2025 Accenture. All rights reserved. Accenture and its logo are trademarks of Accenture.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Invested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2025, and provided a corporate update.

Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies.The test helps clinicians quickly identify heart attack and rule out non-cardiac causes, ensuring patients receive the care they need at the earliest opportunity.The global TSIX clinical study involved more than 13,000 participants, validating performance across a diverse population that reflects real-world healthcare settings.1,2 Basel, 30 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity Troponin T test for diagnosing heart attacks. Presented at the European Society for Emergency Medicine (EUSEM) 20252 and the European Society of Cardiology (ESC) 20251, the study results showed that the Elecsys® Troponin T hs Gen 6 test was able to identify acute myocardial infarction (AMI), or heart attack, and identify those not having an AMI, with a high level of precision.2,3 This supports the efficient triage of patients arriving at the emergency department, ensuring healthcare resources can be focused where they are needed most. This data announcement follows the recent CE Mark approval for the test.

As one of the top three reasons for emergency care visits,4 chest pain creates significant anxiety and uncertainty for patients whilst putting pressure on healthcare services. Yet only one in every ten patients who presents with symptoms will actually be experiencing a heart attack.5 With 49% of emergency departments in Europe reporting overcrowding on a frequent basis,6 the ability to quickly and reliably identify those patients who are suffering from AMI, and to rule out those who are not, is crucial in ensuring the best possible outcomes for patients.

"Coronary artery disease continues to place an immense strain on global health systems, particularly in emergency care, where cases of chest pain are among the most challenging presentations to evaluate,” said Matt Sause, CEO of Roche Diagnostics. “Our new test enables clinicians to detect even the smallest elevations in troponin levels – a critical biomarker for heart attack – with high confidence. This ensures that in a situation when every second counts, patients receive the life-saving care they need at the earliest opportunity, and emergency services can prioritise resources to deliver care effectively to those in urgent need."

About Roche Diagnostics’ commitment to heart health
With a 30-year legacy in troponin innovation, Roche was the first company in the world to introduce high-sensitivity troponin tests. And Roche's troponin test was the first to receive FDA approval. Building on this legacy, the novel test is the first in a series of anticipated approvals for Roche, reflecting the company's vision for the future of coronary artery disease (CAD) management. This includes a portfolio of innovative tests that enable consistent and precise biomarker measurements to be reliably compared across healthcare settings. It also includes future acute coronary syndrome (ACS) offerings that will combine next-generation digital algorithms, biomarkers, near-patient care devices, and laboratory analysers.

About the TSIX Study Program
Forming the basis for regulatory approval, the comprehensive TSIX study program recruited a total of over 13,000 individuals.1,4 It is the first global clinical study program of its kind to be performed in the use of troponin testing, involving patients in the US, China, Japan and the EU, and reflects Roche’s ambition to work towards more standardised care across the world.

The REF-TSIX study was designed to establish the standard upper reference limits (URLs) for troponin levels in the blood.1 These limits represent the highest expected concentration of troponin in a healthy population, providing the benchmarks used to diagnose myocardial infraction. The study prospectively collected plasma and serum samples from a diverse global population to ensure the assay's accuracy across different demographics and healthcare settings. Data presented at European Society of Cardiology congress 2025 showed a 99th percentile URLs of 27 ng/L for the overall population and sex-specific URLs of 18 ng/L for females and 32 ng/L for males.1 These findings confirm the test's consistency and accuracy, meeting the highest benchmarks for clinical diagnostics as recommended by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).7

To validate the clinical performance of the newly established URLs, the prospective, international, multicenter, longitudinal cohort study PERFORM-TSIX enrolled 5,631 patients across 50 sites,2,4 presenting to emergency departments with symptoms of ACS. Up to five samples were collected at intervals after presentation at the emergency department, to provide a detailed assessment of the test's performance across time points.4

The study data demonstrated that the assay was highly effective at detecting heart attacks, meeting its primary endpoint using the universal 99th percentile URL at three hours post emergency department presentation.3 Moreover, the study data showed that 56.6% of patients were able to be discharged in the first hours after presentation with a negative predictive value of 99.7%, underlining its excellent clinical performance.2,4

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Daniels LB et al. Establishing reference values in healthy participants for a next generation cardiac troponin T high-sensitivity assay – the REF-TSIX global reference study. Presented at European Society of Cardiology Congress. 2025 August
[2] Peacock WF et al. Primary results of PERFORM-TSIX, a prospective, international, observational, longitudinal cohort study evaluating clinical performance of the next generation cardiac troponin T high-sensitivity Gen 6 assay in acute coronary syndrome myocardial infarction. Presented at European Society of Emergency Medicine September 2025
[3] F. Hoffmann-La Roche Ltd. Elecsys® Troponin T hs Gen 6 Method Sheet. (v.2.0). 2025
[4] Audrey J. Weiss, Ph.D., and H. Joanna Jiang, Ph.D., Agency for Healthcare Research and Quality, Most Frequent Reasons for Emergency Department Visits, 2018. Available at: https://hcup-us.ahrq.gov/reports/statbriefs/sb286-ED-Frequent-Conditions-2018.jsp
[5] Fanaroff AC, Rymer JA, Goldstein SA, Simel DL, Newby LK. Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review. JAMA. 2015 Nov 10;314(18):1955-65. doi: 10.1001/jama.2015.12735. PMID: 26547467.
[6] Velt KB, Cnossen M, Rood PPM, Steyerberg EW, Polinder S, Lingsma HF; CENTER-TBI investigators. Emergency department overcrowding: a survey among European neurotrauma centres. Emerg Med J. 2018 Jul;35(7):447-448. doi: 10.1136/emermed-2017-206796. Epub 2018 Mar 21. PMID: 29563151.
[7] Aakre, K. M., Saenger, A. K., Body, R., Collinson, P., Hammarsten, O., Jaffe, A. S., ... & Apple, F. S. (2022). Analytical considerations in deriving 99th percentile upper reference limits for high-sensitivity cardiac troponin assays: educational recommendations from the IFCC committee on clinical application of cardiac bio-markers. Clinical chemistry, 68(8), 1022-1030.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Hans Trees, PhD
Phone: +41 79 407 72 58 Sileia Urech
Phone: +41 79 935 81 48 Nathalie Altermatt
Phone: +41 79 771 05 25 Lorena Corfas
Phone: +41 79 568 24 95 Simon Goldsborough
Phone: +44 797 32 72 915 Karsten Kleine
Phone: +41 79 461 86 83 Kirti Pandey
Phone: +49 172 6367262 Yvette Petillon
Phone: +41 79 961 92 50 Dr Rebekka Schnell
Phone: +41 79 205 27 03   Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected] Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected] Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]   Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected]  

Media Investor Release Troponin T Test English

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The Bitcoin community is no stranger to heated debates, but the latest controversy around a rumored Bitcoin Redaction Fork has reignited one of the oldest philosophical battles in crypto: should Bitcoin remain an untouchable, immutable ledger, or should it adapt to external pressures to remove illicit or arbitrary data

Institutional confidence in Solana (SOL) remains strong, making it one of the stable altcoins in the market. Treasury wallets now hold over 20.9 million SOL, roughly 3.64% of the total supply, indicating that large investors are increasingly viewing SOL alongside Bitcoin and Ethereum as part of diversified crypto portfolios.

Companies like Forward Industries and Brera Holdings have disclosed their asset exposure, while ARK has added Solana-related equities and continues to emphasize the network’s expansion.

Meanwhile, speculation about a potential Solana staking ETF has gained momentum; if approved, it could reduce circulating supply and provide yield access, potentially attracting significant new capital into SOL. Mid-cycle analyst targets of $300–$500 reflect this institutional interest along with rising on-chain activity.

SOL's price trends to the upside but with some losses on the daily chart. Source: SOLUSD chart on Tradingview
Firedancer + Alpenglow: Leap in Performance vs. Decentralization Risk
Solana’s technology roadmap provides another boost. Jump Crypto’s Firedancer client proposes SIMD-0370 to remove the fixed compute block limit, allowing higher-performance validators to process more complex blocks and increasing overall throughput.

At the same time, the Alpenglow upgrade (testnet scheduled for December) aims to drastically reduce transaction finality, from approximately 12.8 seconds to 150 milliseconds, making Solana the fastest major chain. These changes could strengthen Solana’s leadership in high-volume DeFi and payments.

However, critics warn that increasing centralization may occur if smaller validators cannot afford the necessary hardware upgrades. The primary challenge is striking a balance between raw speed and validator diversity, which is crucial for evaluating the network’s long-term resilience.

Price Levels: Can Solana (SOL) Bulls Defend $207?
Currently, SOL hovers near $208–$210, up modestly on the day as momentum rebuilds. The market now focuses on $207 as the first support level; a sustained hold preserves the uptrend and keeps a retest of $230–$253 possible, with $257 (the 52-week high) remaining above.

Losing $207 opens the door to $190–$185 as the next demand zone, and a deeper shakeout could test $165–$167. Short-term sentiment is supported by improving tape dynamics, higher spot volumes, and active addresses, although macro factors remain a swing factor.

For traders, the constructive setup is to hold $207, reclaim $223–$230, and then challenge $253–$257. For investors, the thesis relies on three pillars: increasing treasury ownership and potential ETF catalysts, throughput leadership from Firedancer and Alpenglow, and expanding real-world utility across DeFi and commerce.

If Solana maintains support while upgrades happen as scheduled, the path toward new highs strengthens; if not, expect a choppy Q4 with value emerging around the $185 area.

Cover image from ChatGPT, SOLUSD chart from Tradingview

Solana whale sells $31.59M in $SOL, yet charts hint at bullish continuation with eyes on $250 resistance.

Izabela Anna2 min read

30 September 2025, 01:10 AM

Image: ShutterstockSolana ($SOL) has experienced a dynamic trading session as whales aggressively adjust their positions. Today, a single whale reportedly sold $31.59 million in $SOL, highlighting significant profit-taking on minor price pumps, according to analyst TedPillows. Despite this selling pressure, the market shows potential for continued upside if key technical levels hold.

Weekly Chart Hints at Bullish ContinuationAccording to CryptoJelleNL, Solana’s weekly chart shows a prominent cup-and-handle pattern forming above $180 support. The recent bounce near $206 confirms a successful retest of the breakout zone. The $250 mark remains the last hurdle for buyers, and clearing this resistance could trigger a sustained rally toward $300–$340 by year-end. 

Source: X

Conversely, a failure to overcome $250 may result in a brief pullback toward $190–$200 before another attempt. Consequently, the current setup signals bullish continuation if buyers can defend the retest and push decisively through this key resistance.

Daily Chart Insights and Liquidity SweepsOn the daily timeframe, Solana has reclaimed the 50-day simple moving average (SMA) after a brief dip, signaling renewed bullish interest, according to Umair Crypto. The recent sweep below the SMA likely gathered liquidity, setting up a potential move toward resistance around $229–$232. 

Source: X

Nevertheless, traders remain cautious, as weekend closes often spark debates about the validity of short-term movements. A confirmed close above $210 would strengthen the bullish outlook, while slipping back under the SMA could target support levels at $185 and $161.

The RSI has recovered from oversold conditions but remains mid-range, suggesting measured buying interest. With the current price around $214, $SOL has gained 3.56% in the past 24 hours, despite a 1.24% decline over the last week. Trading volumes remain robust, with $7.31 billion exchanged in the last 24 hours, reflecting active investor engagement.

Regulatory Updates Add Another LayerBeyond technical factors, regulatory news continues to influence sentiment. Journalist Eleanor Terrett reports that the SEC has asked issuers of $SOL, $LTC, $XRP, $ADA, and $DOGE ETFs to withdraw their 19b-4 filings following the approval of generic listing standards. Withdrawals could begin this week, removing some previous regulatory hurdles for crypto ETFs.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Izabela Anna

Izabela Anna is a knowledgeable freelance journalist, who boasts over five years of experience covering the cryptocurrency market. Her tenure has seen her navigate through the ebbs and flows of multiple market cycles, giving her a deep understanding within. Her journalistic focus lies in dissecting price action dynamics, scrutinizing the on-chain landscape, and providing insights from a technical perspective, making her a trusted voice in the realm of cryptocurrency reporting.

Read more about

Latest Solana (SOL) News Today

The cryptocurrency market staged a weekend rebound, with Solana (SOL), Dogecoin (DOGE), Cardano (ADA), Ethereum (ETH), and XRP among the top performers. Prices rose between 3% and 4% over the past 24 hours as short liquidations intensified, offering traders fresh optimism after a difficult week.

Bitcoin traded listlessly as September wraps up, caught inside a tight price band and showing signs of weakening momentum.

Based on reports using CryptoQuant data and commentary by Axel Adler, demand cooled after the market failed to hold above $115,000, leaving traders watching a narrow corridor for the next move. The mood is neither euphoric nor panicked — it is cautious.

Mounting Pressure At Descending Highs
Over the past week Bitcoin swung between a local high near $115,550 and a low around $108,400. For the last sessions it settled into an even tighter $108,750–109,740 band. Sellers stepped in at lower highs, keeping the price from climbing back to the prior range.

According to Adler, those descending highs are a warning sign because they show buyers are losing early ground. Immediate resistance sits around $111,000–112,000, based on on-chain flows and exchange behavior.

Move past that and bulls could try to retake $114,000–115,400. Fail to defend $108,750 and the path down may quicken toward $106,000–105,000.

Momentum Has Turned Cautious
CryptoQuant’s 30-day momentum index finished the week near -2%, down from +1% at the start, a swing of three percentage points. Momentum readings this period ranged from -6% to +1%, and only two of seven sessions closed above zero.

Those figures underline how the loss of the $114,000–115,000 support coincided with falling buying pressure. Traders often look for sustained positive momentum to confirm a rally. According to Adler, a clear recovery would need a return above $112K and several days of positive momentum to shift the tone back toward an uptrend.

BTCUSD trading at $112,173 on the 24-hour chart: TradingView
Market Structure And What It Means
The current pattern is a classic consolidation after a failed breakout. Buyers tried and failed to keep prices north of $115,000, and that shortfall left the market in a neutral-to-bearish stance.

Reports have disclosed that the week’s range and the momentum slide make an immediate strong advance unlikely without fresh demand. At the same time, there is no sign of a full-scale sell-off. Liquidity remains present near established supports.

Key Levels To Watch
A decisive push above the $111,000–112,000 resistance band could prompt a test of $114,000–115,400. The $108,600 base remains a key level. A break below it without a swift rebound could open the way toward stronger support between $106,000 and $105,000.

Shifts in on-chain demand and exchange flows are expected to provide clearer signals, as price action alone may appear steady while underlying activity changes.

Featured image from Gemini, chart from TradingView